- Home
- Publications
- Publication Search
- Publication Details
Title
Antibodies to watch in 2021
Authors
Keywords
-
Journal
mAbs
Volume 13, Issue 1, Pages 1860476
Publisher
Informa UK Limited
Online
2021-01-18
DOI
10.1080/19420862.2020.1860476
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Teprotumumab for the Treatment of Active Thyroid Eye Disease
- (2020) Raymond S. Douglas et al. NEW ENGLAND JOURNAL OF MEDICINE
- The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab
- (2020) Pascal Gasser et al. Nature Communications
- Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).
- (2020) Keunchil Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study.
- (2020) Jeff P. Sharman et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacologic Characterization of ALD403, a Potent Neutralizing Humanized Monoclonal Antibody Against the Calcitonin Gene-Related Peptide
- (2020) Leon F. Garcia-Martinez et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
- (2020) Anthony Traboulsee et al. LANCET NEUROLOGY
- Human neutralizing antibodies elicited by SARS-CoV-2 infection
- (2020) Bin Ju et al. NATURE
- Efficacy and safety of eptinezumab in patients with chronic migraine
- (2020) Richard B. Lipton et al. NEUROLOGY
- Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-cMet Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC
- (2020) Jiyeon Yun et al. Cancer Discovery
- Image-Based Single Cell Sorting Automation in Droplet Microfluidics
- (2020) Muhsincan Sesen et al. Scientific Reports
- MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti‐MASP2 antibody narsoplimab
- (2020) S. Elhadad et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
- (2020) Fredrik H. Schjesvold et al. HAEMATOLOGICA
- Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti‐Activin A): Results From a First‐in‐Human Phase 1 Study
- (2020) Frédéric Vanhoutte et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
- (2020) Gilles Salles et al. LANCET ONCOLOGY
- Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial
- (2020) J.I. Silverberg et al. BRITISH JOURNAL OF DERMATOLOGY
- Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)
- (2020) A. Wollenberg et al. BRITISH JOURNAL OF DERMATOLOGY
- Clinical Characteristics and Outcomes of COVID-19 Patients Receiving Compassionate Use Leronlimab
- (2020) Bryant Yang et al. CLINICAL INFECTIOUS DISEASES
- Evinacumab for Homozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Time to Reassess Tocilizumab’s Role in COVID-19 Pneumonia
- (2020) Jonathan B. Parr JAMA Internal Medicine
- Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F
- (2020) Ralph Adams et al. Frontiers in Immunology
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
- (2020) Peter Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan
- (2019) David M. Goldenberg et al. mAbs
- Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan
- (2019) Sumimasa Nagai INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
- (2019) Bruce A C Cree et al. LANCET
- Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
- (2019) Takashi Yamamura et al. NEW ENGLAND JOURNAL OF MEDICINE
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Antibodies to watch in 2020
- (2019) Hélène Kaplon et al. mAbs
- Trial of Anifrolumab in Active Systemic Lupus Erythematosus
- (2019) Eric F. Morand et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
- (2019) Sabue Mulangu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
- (2018) Andreas Wollenberg et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Antibodies to watch in 2018
- (2018) Hélène Kaplon et al. mAbs
- Antibodies to watch in 2019
- (2018) Hélène Kaplon et al. mAbs
- Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2
- (2017) B. Popovic et al. JOURNAL OF MOLECULAR BIOLOGY
- Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
- (2016) Jörg T Regula et al. EMBO Molecular Medicine
- Antibodies to watch in 2017
- (2016) Janice M. Reichert mAbs
- Antibodies to watch in 2016
- (2015) Janice M. Reichert mAbs
- Antibodies to watch in 2014
- (2014) Janice M Reichert mAbs
- Antibodies to watch in 2015
- (2014) Janice M Reichert mAbs
- Antibodies to watch in 2014
- (2013) Janice M Reichert mAbs
- ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade
- (2013) Karen Silence et al. mAbs
- Which are the antibodies to watch in 2013?
- (2013) Janice M. Reichert mAbs
- Antibodies to watch in 2013
- (2013) Janice M Reichert mAbs
- Which are the antibodies to watch in 2012?
- (2012) Janice M. Reichert mAbs
- Antibody-based therapeutics to watch in 2011
- (2011) Janice M. Reichert mAbs
- Antibodies to watch in 2010
- (2010) Janice M. Reichert mAbs
- Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
- (2008) H. M. Horton et al. CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now